$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024036174 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.863M	$3.951M
YoY Change	46.49%	68.92%
% of Gross Profit
Research & Development	$11.35M	$8.309M
YoY Change	106.76%	66.98%
% of Gross Profit
Depreciation & Amortization	$90.00K	$89.00K
YoY Change	76.47%	89.36%
% of Gross Profit
Operating Expenses	$15.21M	$12.26M
YoY Change	87.2%	67.6%
Operating Profit	-$15.21M	-$12.26M
YoY Change	87.2%	67.6%
Interest Expense	$1.148M	$1.225M
YoY Change	737.96%	629.17%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.06M	-$11.04M
YoY Change	79.73%	57.37%
Income Tax	$0.00	$1.000K
% Of Pretax Income
Net Earnings	-$14.06M	-$11.04M
YoY Change	79.73%	57.36%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.21	-$0.17
Diluted Earnings Per Share	-$0.21	-$0.17
COMMON SHARES
Basic Shares Outstanding	65.47M shares	65.47M shares
Diluted Shares Outstanding	65.47M shares	64.47M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$87.31M	$94.46M
YoY Change	183.64%	153.5%
Cash & Equivalents	$26.37M	$17.12M
Short-Term Investments	$60.94M	$77.34M
Other Short-Term Assets	$1.087M	$2.633M
YoY Change	-11.48%	156.88%
Inventory
Prepaid Expenses	$3.229M	$3.183M
Receivables
Other Receivables
Total Short-Term Assets	$91.69M	$100.3M
YoY Change	161.35%	142.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.023M	$1.083M
YoY Change	1.49%	124.69%
Goodwill
YoY Change
Intangibles	$25.00K	$27.00K
YoY Change	-30.56%	-30.77%
Long-Term Investments		$1.469M
YoY Change
Other Assets		$21.00K
YoY Change
Total Long-Term Assets	$2.076M	$3.781M
YoY Change	-22.1%	65.54%
TOTAL ASSETS
Total Short-Term Assets	$91.69M	$100.3M
Total Long-Term Assets	$2.076M	$3.781M
Total Assets	$93.76M	$104.1M
YoY Change	148.4%	138.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$792.0K	$601.0K
YoY Change	32.22%	66.02%
Accrued Expenses	$1.107M	$923.0K
YoY Change	78.55%	48.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$6.482M	$5.263M
YoY Change	-21.41%	-36.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$476.0K	$675.0K
YoY Change	-61.61%	-52.5%
Total Long-Term Liabilities	$476.0K	$675.0K
YoY Change	-61.61%	-52.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.482M	$5.263M
Total Long-Term Liabilities	$476.0K	$675.0K
Total Liabilities	$6.958M	$5.938M
YoY Change	-26.67%	-38.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$546.8M	-$532.7M
YoY Change	8.24%	7.12%
Common Stock	$633.5M	$631.0M
YoY Change	18.76%	18.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$86.81M	$98.18M
YoY Change
Total Liabilities & Shareholders Equity	$93.76M	$104.1M
YoY Change	148.4%	138.55%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$14.06M	-$11.04M
YoY Change	79.73%	57.36%
Depreciation, Depletion And Amortization	$90.00K	$89.00K
YoY Change	76.47%	89.36%
Cash From Operating Activities	-$9.449M	-$11.64M
YoY Change	50.63%	86.13%
INVESTING ACTIVITIES
Capital Expenditures	$28.00K	$83.00K
YoY Change	-94.83%
Acquisitions
YoY Change
Other Investing Activities	$18.67M	$0.00
YoY Change	-481.14%
Cash From Investing Activities	$18.64M	-$83.00K
YoY Change	-442.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	56.00K	-744.0K
YoY Change	-80.62%	-105.63%
NET CHANGE
Cash From Operating Activities	-9.449M	-11.64M
Cash From Investing Activities	18.64M	-83.00K
Cash From Financing Activities	56.00K	-744.0K
Net Change In Cash	9.251M	-12.46M
YoY Change	-180.97%	-279.21%
FREE CASH FLOW
Cash From Operating Activities	-$9.449M	-$11.64M
Capital Expenditures	$28.00K	$83.00K
Free Cash Flow	-$9.477M	-$11.72M
YoY Change	39.06%	87.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3183000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3010000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2633000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1340000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	100338000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	28179000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1865000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	98181000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1377000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1652000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12402000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6645000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13035000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23829000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24290000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17184000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37325000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17122000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17122000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23767000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	1469000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1083000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1061000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1181000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1477000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2024Q2	us-gaap	Assets Assets	104119000	usd
CY2023Q4	us-gaap	Assets Assets	30750000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	601000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	204000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	923000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	691000	usd
CY2024Q2	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1068000	usd
CY2023Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	921000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1870000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2979000	usd
CY2024Q2	us-gaap	Debt Current DebtCurrent	0	usd
CY2023Q4	us-gaap	Debt Current DebtCurrent	1334000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	801000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5263000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8508000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	675000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1055000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	5938000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9563000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65465876	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	65000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	630916000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	534375000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-87000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-532718000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513213000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	98181000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21187000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	104119000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30750000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8309000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4976000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2379000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65465876	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20222672	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20222672	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14349000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9901000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3951000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2339000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6736000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4783000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	12260000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	7315000	usd
	us-gaap	Operating Expenses OperatingExpenses	21085000	usd
	us-gaap	Operating Expenses OperatingExpenses	14684000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12260000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7315000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21085000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14684000	usd
CY2024Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	1283000	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	471000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1720000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	886000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	58000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	168000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	139000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	353000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11035000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7012000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19504000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14151000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-11036000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-7013000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19505000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14152000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-42000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-87000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11078000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7013000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19592000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14152000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64465185	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64465185	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19101969	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19101969	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47105993	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47105993	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17979343	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17979343	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21187000	usd
CY2024Q1	rgls	Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts	93897000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	31000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	985000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent	-45000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8469000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	107588000	usd
CY2024Q2	rgls	Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts	-43000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-152000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent	-42000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-11036000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	33291000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	21000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	410000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent	12000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7139000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	26595000	usd
CY2023Q2	rgls	Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts	14003000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	382000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-7013000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	33997000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19505000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14152000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	170000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	95000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2850000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	792000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-579000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-56000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	42000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	81000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	172000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1314000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-821000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	396000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	188000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	358000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-371000	usd
	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	147000	usd
	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-497000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1109000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-676000	usd
	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-51000	usd
	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-40000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1612000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-548000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20379000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14366000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	78315000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	15000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	312000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78627000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14999000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	93854000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14003000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-119000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92361000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37263000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17184000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37325000	usd
	us-gaap	Interest Paid Net InterestPaidNet	60000	usd
	us-gaap	Interest Paid Net InterestPaidNet	276000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	33000	usd
CY2024Q2	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	651700000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	95900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div>Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46948938	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41248630	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28772824	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20758912	shares
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	78894000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	87000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	78807000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	94900000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	23084000	usd
	rgls	Number Of Amendments NumberOfAmendments	10	amendment
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65465876	shares
CY2024Q2	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14006000	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	61189000	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1865000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	382000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2850000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	792000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	404000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	824000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	277000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1505000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1422000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	747000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	675000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-24-036174-index-headers.html	Edgar Link	pending
0001628280-24-036174-index.html	Edgar Link	pending
0001628280-24-036174.txt	Edgar Link	pending
0001628280-24-036174-xbrl.zip	Edgar Link	pending
ex-311x20240630.htm	Edgar Link	pending
ex-312x20240630.htm	Edgar Link	pending
ex-321x20240630.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20240630.htm	Edgar Link	pending
rgls-20240630.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rgls-20240630_cal.xml	Edgar Link	unprocessable
rgls-20240630_def.xml	Edgar Link	unprocessable
rgls-20240630_pre.xml	Edgar Link	unprocessable
rgls-20240630_lab.xml	Edgar Link	unprocessable
rgls-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2024 Q3 Form 10-Q Financial Statement

#000162828024036174 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2024 Q3 Form 10-Q Financial Statement

#000162828024036174 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls